Hammond R, Bull C, Houghton C R
Gynaecologic Oncology Unit, University of Sydney, New South Wales.
Aust N Z J Obstet Gynaecol. 1992 Aug;32(3):267-9. doi: 10.1111/j.1479-828x.1992.tb01963.x.
During a 10-year period from January 1, 1979, 59 patients out of a total of 203 undergoing definitive treatment for epithelial ovarian cancer were managed with primary adjuvant whole abdominal radiotherapy after initial cytoreductive surgery. The median survival of this group was 53 months. The serious morbidity rate was approximately 8% with 4 laparotomies for bowel complications and 1 death following radiation related liver failure. This form of adjuvant therapy in appropriately selected patients with minimal residual disease merits further evaluation against other forms of therapy such as systemic or intraperitoneal chemotherapy.
在1979年1月1日起的10年期间，203例接受上皮性卵巢癌根治性治疗的患者中，有59例在初次肿瘤细胞减灭术后接受了全腹原发性辅助放疗。该组患者的中位生存期为53个月。严重并发症发生率约为8%，有4例因肠道并发症接受剖腹手术，1例因放疗相关肝衰竭死亡。对于适当选择的残留病灶极少的患者，这种辅助治疗形式值得与其他治疗形式（如全身化疗或腹腔内化疗）进行进一步评估。
